氯特胺 | 10389-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 氯特胺
• 英文名称: 2-(2-chloro-phenyl)-1,1-dimethyl-ethylamine; hydrochloride
• 英文别名: 2-(2-Chlor-phenyl)-1,1-dimethyl-aethylamin; Hydrochlorid；1-(2-chlorophenyl)-2-methylpropan-2-amine hydrochloride；1-(2-chlorophenyl)-2-methylpropan-2-amine;hydron;chloride
• CAS: 10389-72-7
• 化学式: C₁₀H₁₄ClN*ClH
• 分子量: 220.142
• InChiKey: QNJJECIHYZJXRL-UHFFFAOYSA-N

物化性质

• 熔点：
  245-246°

计算性质

• 辛醇/水分配系数(LogP)：
  3.04
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  4-(4-氯-6-(2-(二氟甲基)-1H-苯并[d]咪唑-1-基)-1,3,5-三嗪-2-基)吗啉 、 氯特胺 在 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以25%的产率得到4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(1-(2-chlorophenyl)-2-methylpropan-2-yl)-6-morpholino-1,3,5-triazin-2-amine
  参考文献：
  名称：

  (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES

  摘要：

  本文提供了（α-取代的芳基氨基或杂环芳基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑类化合物，例如，式I的化合物，以及它们的药物组合物、制备方法，以及作为治疗增殖性疾病的药剂或药物的用途。

  公开号：

  US20120252802A1

文献信息

• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• [EN] HYDROGEN PEROXIDE SENSORS BASED UPON PHOTO-INDUCED ELECTRON TRANSFER<br/>[FR] DÉTECTEURS DE PEROXYDE D’HYDROGÈNE BASÉS SUR LE TRANSFERT D’ÉLECTRONS PAR PHOTO-INDUCTION
  申请人：OPTI MEDICAL SYSTEMS

  公开号：WO2011011605A1

  公开（公告）日：2011-01-27

  The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q+ is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q+. The invention also provides methods of detecting and determining the presence of analytes and/or hydrogen peroxide in a sample, as well as a substrate that comprises the compound of formula I.

  该发明提供了I式化合物F-L-Q（I），其中F包括一种荧光团，能够在激发波长吸收能量，并在缺乏淬灭剂的情况下，在发射波长发射能量，该发射波长不同于激发波长；Q包括一种淬灭剂；L包括一个连接基团，具有两个末端，其中一个末端与F共价结合，另一个末端与Q共价结合。这些化合物能够进行可逆反应（1），如下所示：（1）其中Q +是Q的氧化形式，表示没有淬灭剂，Ox包括一种氧化剂，能够将Q氧化为其氧化形式Q，而Red包括一种还原剂，能够将Q转化回其还原形式Q。当受到能量辐射并且Q存在于其氧化形式Q +时，这些化合物可以进行光诱导电子转移。该发明还提供了检测和确定样品中分析物和/或过氧化氢存在的方法，以及包含I式化合物的基板。
• Use of sulfamate derivatives for treating impulse control disorders
  申请人：——

  公开号：US20010023254A1

  公开（公告）日：2001-09-20

  Impulse Control Disorders (ICD's) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others. The present invention comprises methods for the treatment or prevention of ICD's using a class of sulfamates of the following formula: 1 wherein X is CH 2 or oxygen, and R 1 , R 2 , R 3 , R4 and R 5 are as herein defined. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention are also disclosed.

  冲动控制障碍(ICD)的特征为在无法抵制的冲动下进行有害行为。ICD的本质特征是无法抵制冲动、驱动力或诱惑，并执行对个人或他人有害的行为。本发明涉及使用以下公式的磺酰胺类治疗或预防ICD的方法：1其中X为CH2或氧，R1、R2、R3、R4和R5如本文所定义。此外，本发明还揭示了含有公式(I)化合物的制药组合物以及其使用方法和中间体。